FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

93

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® for the First-Line Treatment of Metastatic HNSCC

http://www.businesswire.com/news/home/20190211005256/en/FDA-Grants-Priority-Review-Merck%E2%80%99s-Supplemental-Biologics/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==